Clinical Observation And Mechanism Research On The Treatment Of Phlegm Stasis And Collaterals For The Acute Ischemic Stroke By Sanqiyufeng Capsule

Objective: Observing the changes of TCM syndrome score,NIHSS score,ADL score and adverse reaction before and after the treatment of phlegm and stasis collaterals acute ischemic stroke with Sanqiyufeng capsule was the precondition of this clinical study.In this way,the clinical efficacy and safety of the drug were evaluated.It is hoped that the study can provide theoretical and practical basis for the clinical application of the Sanqiyufeng capsule in the treatment of acute ischemic stroke of phlegm and collaterals,and provide support for the further development of new drugs.Methods: Methods 66 patients with acute cerebral infarction who met the inclusion criteria from June 2017 to February 2018 in the second Chinese Medicine Hospital of Luoyang were selected.There were 33 cases in the observation group and the control group according to the random grouping method.During the study period,3 cases were lost in the observation group and the control group,and the final clinical data were not included in the cases.The methods were as follows: the control group was given Aspirin Enteric-coated Tablets(100mg,QD,PO),Sodium Ozagrel and Sodium Chloride Injection(80mg,BID,IVGTT)and Edaravone Injection(30mg,BID,IVGTT)on basic treatment,and the observation group took Sanqiyufeng capsule on the basis of the conventional control group,2 capsules each time,3 times a day.The two groups were at the end of 14 days.The TCM syndrome score,NIHSS scale score and ADL scale were compared before and fourteenth days,and the clinical efficacy and safety of the Sanqiyufeng capsule were evaluated by SPSS22.0 software.Results: According to the clinical statistical results,the results of the TCM syndrome based on TCM syndrome score showed that the observation group recovered 4 cases,effective remarkably 11,effective 15,invalid 2,and the total effective rate was 93.75%;the control group recovered 1 cases,the effective remarkably 5,the effective 14,the invalid 11,the total effective 64.52%,the improvement of the TCM syndrome after the treatment was obviously superior.In the control group,the score of group and the curative effect of Chinese medicine were all P < 0.05.The results of NIHSS and ADL scores before and after treatment were compared.The results showed that the two groups of neurological deficits and daily life ability after treatment were significantly improved,and there was a statistical significance of P < 0.05.After treatment,the results of the two groups of NIHSS and ADL were compared.The observation group was better than the control group.There were significant differences in the two groups,with statistical significance,P(NIHSS)=0.044,P(ADL)=0.036,all < 0.05.In terms of safety,there were no obvious adverse reactions in the two groups.Conclusion: The curative effect of " Sanqiyufeng capsule " in treating acute ischemic stroke phlegm and stasis syndrome,not only obviously improve the TCM syndrome score,increase the curative effect of traditional Chinese medicine,but also improve the clinical effect in promoting the recovery of nerve function and improving the living ability,which is better than the control group with pure western medicine.No adverse safety incidents occurred during the study,which is worthy of clinical recommendation.